UnitedHealth: The Great Reversal Is Coming (Earnings Preview)

UnitedHealth Group (UNH) stock has fallen over 40% YTD due to Q1 2025 EPS and revenue misses, a 12% cut to FY2025 guidance, and a rising Medical Care Ratio (MCR) projected at 87.5% for FY2025 amid Medicare Advantage cost pressures. However, the stock has rebounded 9.56% from its mid-May lows, with a new CEO now focused on MCR improvement. Analysts anticipate a 2H 2025 recovery driven by cost controls and stronger performance from UnitedHealthcare and Optum Rx, making the upcoming Q2 earnings call crucial for future guidance. One analyst reiterates a "Buy" rating, citing significant undervaluation and substantial reversal potential as current pricing reflects peak negativity.

Analysis

UnitedHealth Group (UNH) has experienced significant headwinds, reflected in a year-to-date stock decline of over 40%. This was precipitated by a Q1 2025 earnings miss, where adjusted EPS of $7.20 fell 9 cents below consensus, and a revenue miss of 1.82% against expectations. Compounding this, management slashed the FY2025 adjusted EPS outlook by approximately 12% and signaled a deteriorating margin profile. The core operational issue is a rising Medical Care Ratio (MCR), which climbed to 84.8% in Q1 and is projected to reach 87.5% for the full year, driven by higher utilization in Medicare Advantage and challenges at Optum Health. However, several potential catalysts for a recovery are on the horizon. A key development is the return of former CEO Stephen J. Hemsley, who successfully led the company from 2006 to 2017 and is now prioritizing MCR improvement. Furthermore, while Optum Health's outlook was reduced, the UnitedHealthcare and Optum Rx segments are expected to deliver stronger-than-anticipated revenue in the second half of 2025. The stock's valuation appears depressed, with its forward price-to-sales ratio near its lowest level since 2000, suggesting the market has priced in peak pessimism. The upcoming Q2 earnings call is therefore a pivotal event, where investor focus will be on new management's forward guidance rather than backward-looking results.

Key Decisions for Investors

• Given the stock's significant YTD underperformance and valuation at multi-decade lows on a forward P/S basis, investors could view the current price as an attractive entry point, as negative sentiment and operational challenges appear to be fully priced in.
• Investors should closely monitor the upcoming Q2 earnings call, focusing on any revised FY2025 guidance and new management's strategy for controlling the Medical Care Ratio, which will be the primary catalyst for a potential re-rating.
• While there is significant upside potential, recognize the risk that if forward-looking commentary disappoints, the stock could face further downside, making any position contingent on a positive turnaround narrative from management.
• Consider the relative strength expected from the UnitedHealthcare and Optum Rx segments in the second half of the year as a potential buffer against continued weakness at Optum Health.